Renato Mantegazza - Concepedia

Author

Renato Mantegazza

Fondazione IRCCS Istituto Neurologico Carlo Besta ORCID

Also Known As

AND RENATO MANTEGAZZA, Antonio Uccelli, C. Sommer, Francesco Ottavio Logullo, Henning Andersen, Howard, James F, Howard, James F., Mantegazza R, Mantegazza, R., Mantegazza, Renato

530

Publications

16.4K

Citations

H-Index

236

Concepts

All Affiliations

Fondazione IRCCS Istituto Neurologico Carlo Besta University of Milan Istituti di Ricovero e Cura a Carattere Scientifico University of North Carolina at Chapel Hill Università Cattolica del Sacro Cuore

About

Renato Mantegazza is an author at Fondazione IRCCS Istituto Neurologico Carlo Besta specializing in medicine, immunology, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	42	115	7.1K
2	Health Sciences	10	10	276
3	Natural Sciences	6	6	205
4	Public Health	4	4	135
5	Engineering	1	1	85

Renato Mantegazza

224

Publications

13.7K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study James F. Howard, Kimiaki Utsugisawa, Michael Benatar, The Lancet Neurology Multicentre StudyPharmacologyMedicineMyasthenia GravisNeuromuscular Blockade	2017	745
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial James F. Howard, Vera Bril, Tuan Vu, The Lancet Neurology MedicineGeneralised Myasthenia Gravis	2021	587
Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis Ezio Gerdoni, Barbara Gallo, Simona Casazza, Annals of Neurology	2007	481
A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis Paraskevi Zisimopoulou, Panagiota Evangelakou, John Tzartos, Journal of Autoimmunity Autoimmune DiseaseMedicinePathologyComprehensive AnalysisDermatology	2013	317
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis Donald B. Sanders, I. K. Hart, Renato Mantegazza, Neurology	2008	308
Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. Pia Bernasconi, E Torchiana, Paolo Confalonieri, Journal of Clinical Investigation	1995	290
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis James F. Howard, Vera Bril, Ted M. Burns, Neurology	2019	268
Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis Srikanth Muppidi, Kimiaki Utsugisawa, Michael Benatar, Muscle & Nerve	2019	239
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study Vera Bril, Artur Drużdż, Julian Großkreutz, The Lancet Neurology Clinical TrialsGeneralised Myasthenia GravisPharmacotherapyMedicineAnesthesiology	2023	227
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial Gil I. Wolfe, Henry J. Kaminski, Inmaculada Aban, The Lancet Neurology	2019	216

Page 1